

Smart Ten Trust

Series 39


A 15 Month Unit Investment Trust

Investment Objective

The trust seeks to maximize total return potential through capital appreciation and current dividend income. There is no guarantee that the investment objective of the trust will be achieved.

Investment Strategy

The trust seeks to achieve its objective by attempting to outperform the Dow Jones Industrial Average™ (DJIA). The trust invests approximately equal amounts (as of the trust's inception) in the ten common stocks in the DJIA that have the highest dividend yields as of January 21st, 2025.



Description of Portfolio

INCEPTION DATE:	February 4, 2025
TERMINATION DATE:	May 12, 2026
INITIAL OFFER PRICE	\$10.00
MINIMUM INVESTMENT	100 units (may vary by selling firm)
NUMBER OF ISSUES:	10
DISTRIBUTIONS: ¹	MONTHLY (if any)
HISTORICAL 12-MONTH DISTRIBUTION: ²	\$0.3131 (per unit)
CUSIP (CASH):	83207W 262
CUSIP (REINVESTMENT):	83207W 270
FEE-BASED CUSIP (CASH):	83207W 288
FEE-BASED CUSIP (REINVESTMENT):	83207W 296
TICKER:	STSTMX

¹Distributions, if any, will be made commencing on February 25, 2025.

²The Historical 12-Month Distribution of Trust Holdings is calculated by taking the weighted average of the regular income distributions paid by the securities included in the trust's portfolio over the 12 months preceding the trust's date of deposit reduced to account for the effects of trust fees and expenses. This historical distribution is for illustrative purposes only and is not indicative of amounts that will actually be distributed by the trust. The distributions paid by the trust may be higher or lower than the amount shown above due to factors including, but not limited to, changes in the price of trust units, changes (including reductions) in distributions paid by issuers, changes in actual trust expenses and sales of securities in the portfolio. There is no guarantee that the issuers of the securities included in the trust will pay any distributions in the future.

Hypothetical Total Returns³

Year	Strategy	DJIA
2000	3.57%	-4.71%
2001	-7.22%	-5.43%
2002	-11.17%	-14.97%
2003	25.52%	28.23%
2004	1.82%	5.30%
2005	-7.43%	1.72%
2006	27.03%	19.03%
2007	-0.31%	8.87%
2008	-40.30%	-31.92%
2009	14.88%	22.70%
2010	18.11%	14.10%
2011	13.82%	8.34%
2012	7.00%	10.24%
2013	31.52%	29.63%
2014	8.06%	10.02%
2015	0.08%	0.23%
2016	17.37%	16.46%
2017	20.60%	28.11%
2018	-2.46%	-3.48%
2019	16.70%	25.34%
2020	-10.27%	9.72%
2021	13.42%	20.95%
2022	-6.87%	-6.86%
2023	0.70%	16.18%
Thru 12/31/24	8.31%	14.99%

³These are hypothetical returns of the Smart Ten Trust strategy ("strategy") but not the trust or any prior series. The strategy was created with the benefit of hindsight. Past performance is not indicative of future results and actual performance of the portfolio may be lower or higher than the future performance of the strategy. Some of these returns are the result of extraordinary market events and are not expected to be repeated. Strategy performance is based on a calendar year strategy and, while trusts may be created at various times during the year, they generally have 15-month terms. Consult your tax advisor for possible tax consequences associated with this investment. Units may be well suited for an IRA or other qualified plan.

Hypothetical strategy returns reflect a maximum sales charge of 1.85% in each year shown, plus additional trust fees and expenses, but do not include brokerage commission or taxes. Returns assume that all dividends received during a year are reinvested as of their distribution date. In addition, the strategy's hypothetical performance will vary from that of investing in the strategy stocks because it may not be weighted the same as the strategy stocks and may not be fully invested at all times. Investors should also be aware that the strategy may lose money or underperform the index in any given year.

The DJIA® consists of 30 U.S. stocks chosen by the editors of the Wall Street Journal as being representative of American Industry. This index cannot be purchased directly by investors. The index returns are not adjusted for trust sales fees and expenses, as they are not available to invest in directly.

Investors should consider the trust's investment objective, risks, charges and expenses carefully before investing. The prospectus contains this and other information relevant to an investment in the trust. Please read the prospectus carefully before you invest. If a prospectus did not accompany this literature, please contact SmartTrust at (888) 505-2872 to obtain a free prospectus.

Hennion & Walsh is a member of FINRA/SIPC. 2001 Route 46, Waterview Plaza, Parsippany, NJ 07054 (888) 505-2872 www.smarttrustuit.com

NOT FDIC INSURED • NOT BANK GUARANTEED • MAY LOSE VALUE

Sales Charges and Estimated Expenses⁴

(Based on a \$10 public offering price)

Standard Accounts	Transactional Sales Charge:	Initial	0.000%
		Deferred	1.350%
	Creation & Development Fee: ⁵		0.500%
	Maximum Sales Charge:		1.850%
	Estimated Organization Costs: ⁶		0.668%
	Estimated Annual Operating Expenses: ⁷		0.221%

The initial sales charge is paid at the time of purchase and is the difference between the total sales charge (maximum of 1.85% of the public offering price) and the sum of the remaining deferred sales charge and the total creation and development fee. When the public offering price per unit is less than or equal to \$10, you will not pay an initial sales fee. When the public offering price per unit is greater than \$10 per unit, you will pay an initial sales fee.

The deferred sales charge is a charge of \$0.135 per unit and will be deducted in three monthly installments commencing on May 20, 2025. The initial and deferred sales fees do not apply to fee-based accounts. Please see the prospectus for sales charge details.

Fee/Wrap Accounts	Creation & Development Fee: ⁵	0.500%
	Maximum Sales Charge:	0.500%
	Estimated Organization Costs: ⁶	0.668%
	Estimated Annual Operating Expenses: ⁷	0.221%

⁴Percentages are based on a \$10.00 per unit offering price. For unit prices other than \$10.00, percentages of initial sales charge, creation and development fee, and deferred sales charges will vary. Early redemption will still cause payment of the deferred sales charge. The table above shows the initial offering period sales charges only.

⁵The creation and development fee is a charge of \$.050 per unit collected at the end of the initial offering period. If the price you pay exceeds \$10 per unit, the creation and development fee will be less than 0.50%; if the price you pay is less than \$10 per unit, the creation and development fee will exceed 0.50%.

⁶Estimated Organization Costs are assessed on a fixed dollar amount per unit basis of \$0.0668 per unit and may be less than estimates. For additional information on organization costs please see the prospectus.

⁷Estimated Annual Operating Expenses include fees for administration, bookkeeping, the trustee, the supervisor and acquired fund fees and expenses. This expense is an estimate based upon an estimated trust size. If the trust does not reach or falls below the estimated size, the actual amount of the operating expenses as a % of unit price may exceed the amount reflected. Please see "Trust Expenses and Charges" in the trusts prospectus for additional information.

Portfolio Holdings as of February 4, 2025:

EQUITY SECURITIES – 100.00%	
Communication Services – 9.95%	
VZ	Verizon Communications Inc.
Consumer Discretionary – 10.01%	
MCD	McDonald's Corporation
Consumer Staples – 19.90%	
KO	The Coca-Cola Company
PG	The Procter & Gamble Company
Energy – 10.03%	
CVX	Chevron Corporation
Health Care – 29.96%	
AMGN	Amgen Inc.
JNJ	Johnson & Johnson
MRK	Merck & Co., Inc.
Information Technology – 20.15%	
CSCO	Cisco Systems, Inc.
IBM	International Business Machines Corporation

Risk Considerations

Unitholders can lose money by investing in this trust. An investment in units of the trust should be made with an understanding of the risks related to the trust, such as the following:

- Security prices will fluctuate. The value of your investment may fall over time. The potential economic impacts of the novel form of coronavirus disease first detected in 2019 ("COVID-19"), which spread rapidly around the globe which led the World Health Organization to declare the COVID-19 outbreak a pandemic in March 2020, are not fully known. The COVID-19 pandemic, or any future public health crisis, are impossible to predict and could result in adverse market conditions which may negatively impact the performance of the securities in the portfolio and the trust.
- The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your units. This may occur at any point in time, including during the initial offering period. Securities selected by the sponsor may not perform as expected during a "pullback."
- The issuer of a security may be unwilling or unable to declare dividends in the future or may reduce the level of dividends declared. This may reduce the level of distributions the trust pays which could reduce your income and cause the value of your units to fall. The COVID-19 pandemic has resulted in a decline in economic activity and caused many companies to reduce the level of dividends declared and many companies may be unwilling or unable to declare dividends for the foreseeable future. It is also possible that current or future government aid programs could limit companies from paying dividends as a condition to receiving government aid or discourage companies from doing so.
- The trust's performance might not sufficiently correspond to published hypothetical back-tested performance of the trust's investment strategy. This can happen for reasons such as an inability to exactly replicate the weightings of securities in the strategy or be fully invested, timing of the trust offering or timing of your investment, and trust expenses. Hypothetical back-tested performance is not actual past performance of this or any trust. Hypothetical back-tested performance is based on application of a trust's investment strategy as of a particular time.
- The trust is considered to be concentrated in securities issued by companies in the health care sector. Negative developments in this sector will affect the value of your investment more than would be the case in a more diversified investment. General risks of companies in the health care sector include the impacts of existing and changing government regulations and spending, increasing competition from new products or services, loss of patent and other intellectual property protection and substantial research and development costs.
- The trust's portfolio consists of a relatively small number of securities. Under normal circumstances, the trust will invest in only ten securities. As a result, negative developments related to these securities will affect the value of your investment more than would be the case in a more diversified investment.
- The trust is not actively managed. Except in limited circumstances, the trust will hold, and continue to buy, shares of the same securities even if their market value declines.
- The sponsor may offer successive trusts with similar portfolios thereby allowing the investor to pursue the same strategy over a number of years. Investors should consider their ability to pursue investing in successive trusts, if available. There may be tax consequences associated with investing in the trust and rolling over an investment from one trust to the next.

The "Dow Jones Industrial Average" is a product of S&P Dow Jones Indices LLC or its affiliates ("SPDJI") and Dow Jones Trademark Holdings LLC, and has been licensed for use by the trust. Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by the trust. Dow Jones®, Dow Jones Industrial Average™, DJIA®, and The Dow® are trademarks of Dow Jones Trademark Holdings LLC and have been licensed for use by SPDJI and the trust. The trust is not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, their respective affiliates, or Dow Jones Trademark Holdings LLC and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the Dow Jones Industrial Average.